334.1K XNAS Volume
XNAS 17 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Katarina Luptakova | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 44,250 | 244,883 | - | - | Common Stock | |
| Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 638,000 | 638,000 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 44,250 | 132,750 | - | - | Restricted Stock Units | |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 5,000 | 5,000 | - | - | Common Stock | |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 01 Jan 2025 | 1,803 | 3,197 | - | 1.0 | 1,774 | Common stock |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 5,000 | 15,000 | - | - | Restricted Stock Units | |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 251,000 | 251,000 | - | - | Stock Option (right to buy) | |
| Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 19,375 | 58,125 | - | - | Restricted Stock Units | |
| Christopher Frankenfield | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 01 Jan 2025 | 6,954 | 12,421 | - | 1.0 | 6,841 | Common stock |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 16,625 | 16,625 | - | - | Common Stock | |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 16,625 | 49,875 | - | - | Restricted Stock Units | |
| Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 19,375 | 19,375 | - | - | Common Stock | |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Christopher Frankenfield | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2024 | 52,000 | 52,000 | - | - | Stock Option (right to buy) | |
| Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Sara M. Bonstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Christina Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 59,333 | 59,333 | - | - | Stock Option (right to buy) | |
| Christopher Frankenfield | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 208,000 | 208,000 | - | - | Stock Option (right to buy) | |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 474,000 | 474,000 | - | - | Stock Option (right to buy) | |
| Kevin Brennan M. | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Frankenfield Christopher | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 77,500 | 77,500 | - | - | Restricted Stock Units | |
| Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 177,000 | 177,000 | - | - | Restricted Stock Units | |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 66,500 | 66,500 | - | - | Restricted Stock Units | |
| Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 136,500 | 136,500 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 700,000 | 700,000 | - | - | Stock Option (right to buy) | |
| Christopher Frankenfield | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Christina Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Sara Bonstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 136,500 | 136,500 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 26,400 | 26,400 | - | - | Stock Option (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Michael Ross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Sara Bonstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Christina Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Martin H. Huber | PRESIDENT AND HEAD OF R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Martin H. Huber | PRESIDENT OF R&D AND CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Salvatore Giovine | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 49,500 | 49,500 | - | - | Stock Option (right to buy) | |
| Yuan Xu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 26,400 | 26,400 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 44,033 | 44,033 | - | - | Stock Option (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 65,528 | 65,528 | - | - | Stock Option (right to buy) | |
| Salvatore Giovine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 28,755 | 28,755 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director, CEO and President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 50,041 | 50,041 | - | - | Stock Option (right to buy) | |
| Martin H. Huber | President of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 157,058 | 157,058 | - | - | Stock Option (right to buy) | |
| Michael Ross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 26,400 | 26,400 | - | - | Stock Option (right to buy) |